Proteomic Biomarker Testing Services Using CNS Panel 220 Argo NULISA Platform
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the Intramural Center for Alzheimer’s Disease and Related Dementias, is conducting market research through this Sources Sought Notice to identify qualified and interested sources for Proteomic Biomarker Testing Services. The requirement involves using the CNS panel 220 Argo NULISA platform for Government-furnished biospecimens to support Alzheimer's disease and related dementias (AD/ADRD) research. This is for information and planning purposes only and is not a solicitation. Responses are due May 13, 2026, at 11:00 AM EST.
Scope of Work
The Government seeks high-throughput, quality-controlled proteomic testing services. Contractors will perform CNS panel 220 Argo NULISA proteomic analysis on biospecimens such as cerebrospinal fluid (CSF) and EDTA plasma. Key tasks include:
- Processing up to 8,970 samples per year across various cohorts (e.g., PREVENT-AD, Geneva, DABNI/SPUN, K-ROAD).
- Running pooled Government samples for normalization and utilizing a NuLISA quality control bridging cohort to assess analytical performance, normalize datasets, and control for variations.
- Maintaining a throughput capacity to prepare NuLISA libraries for up to 2,400 samples per week.
- Providing raw sequencing data in FASTQ format within two weeks of library receipt, and final QC-reviewed results within an additional two weeks.
- Adhering to manufacturer requirements, accepted industry standards, and all applicable federal, state, and local laws.
Contract & Timeline
- Type: Sources Sought / Market Research
- Agency: Department of Health and Human Services (HHS), National Institutes of Health (NIH)
- PSC: Q301 – Medical Laboratory Testing
- NAICS: 541380 – Testing Laboratories and Services
- Anticipated Period of Performance: Base Year (Aug 2026 - Jul 2027) + two Option Years.
- Place of Performance: Contractor's facility.
- Set-Aside: None specified; market research will determine set-aside feasibility.
- Response Due: May 13, 2026, 11:00 AM EST
- Published: May 7, 2026
Submission Requirements & Evaluation
Interested parties must submit an electronic capability statement, limited to 5 pages (excluding cover page), in PDF format. The statement should address:
- Company Information: UEI, CAGE, business size (NAICS 541380), socioeconomic status.
- Technical Capability: Experience with CNS panel 220 Argo NULISA testing or equivalent, biospecimen processing, throughput capacity, QC procedures, data management, and security.
- Relevant Experience: Up to three recent and relevant projects similar in scope, size, and complexity.
- Business and Acquisition Strategy: Interest as prime/subcontractor, suitability for small business set-aside, and contract type recommendations.
Responses will inform the Government's acquisition strategy, including potential set-asides, and help identify capable sources. This notice does not obligate the Government to award a contract.